Fecal Microbiota Transplantation

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

MaaT Pharma
MaaT PharmaFrance - Lyon
1 program
1
fecal microbiota transferPhase 21 trial
Active Trials
NCT03359980CompletedEst. Nov 2020
Bristol Myers Squibb
1 program
Allogenic Fecal Microbiota TransplantationN/A1 trial
Active Trials
NCT04577729Terminated5Est. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MaaT Pharmafecal microbiota transfer
Bristol Myers SquibbAllogenic Fecal Microbiota Transplantation

Clinical Trials (2)

Total enrollment: 5 patients across 2 trials

NCT03359980MaaT Pharmafecal microbiota transfer

Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer

Start: Aug 2018Est. completion: Nov 2020
Phase 2Completed
NCT04577729Bristol Myers SquibbAllogenic Fecal Microbiota Transplantation

The IRMI-FMT Trial

Start: May 2021Est. completion: Jun 20235 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space